Magnetic Resonance Imaging (MRI) and radiological study of Rheumatoid Arthritis treated with Adalimumab and non-biological agents to assess the impact of disease control on MRI manifestations and joint structure preservation.

Emeritus Research0 sites180 target enrollmentStarted: August 24, 2012Last updated: January 13, 2020

Conditions

Trial Snapshot

No summary available.

•1.Stable therapy for at least 6 months, non-biological DMARDs with a DAS-28 of < 2.6
•2.Stable therapy for at least six months, Adalimumab, DAS-28 < 2.6.
•3.Stable therapy for at least six months, Adalimumab, DAS -28 > 3.2
•4.Rheumatoid factor or CCP positive at some stage in the course of their disease
•5.Capable of undergoing MRI examinations.
•6.Capable of understanding the Informed Consent document.
•7.Anticipate stable treatment for at least 18 months
•8.Reliable to attend for the review

•1.Contra-indications to MRI examination, including but not limited, to metallic brain clips, previous stapedectomy, cardiac pacemaker, profound claustrophobia or inability to lie in the MRI machine in an appropriate position to obtain quality images.
•2.Women who are pregnant or breast feeding or planning to become pregnant during the study.
•3.Treatment with any investigational therapy within 3 months
•4.Not willing to return for required follow-up visits or there is a clear demonstration of likely poor compliance;
•5.Any other medical condition (including current infections) that, in the judgment of the Investigator, would prohibit the patient from participating in the study.

Sponsor

Emeritus Research